Unilateral edema due to a thiazolidinedione [8]

Diabetes Care

Volumn 26, Issue 9, 2003, Pages 2700-

  Bell, David S H ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; FUROSEMIDE; GLIMEPIRIDE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN GLARGINE; METFORMIN; ROSIGLITAZONE; TROGLITAZONE; VASCULOTROPIN;

ADULT; CASE REPORT; DEEP VEIN THROMBOSIS; DISEASE DURATION; DRUG WITHDRAWAL; HUMAN; LEG EDEMA; LETTER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PROTEINURIA;

DIABETES MELLITUS, TYPE 2; EDEMA; HUMANS; HYPOGLYCEMIC AGENTS; LEG; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 0041321523     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.9.2700     Document Type: Letter

References (4)

1. Avandia (rosiglitazone maleate) [package insert]. Philadelphia, SmithKline Beecham Pharmaceuticals, 2000
2. Actos (pioglitazone hydrochloride) [package insert]. Lincolnshire, IL, Takeda Pharmaceuticals, 2000
3. Baron AD, Brechtel G: Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am J Physiol 265: E61-E67, 1993
4. Baba T, Shimada K, Neugenhauer S, Yamada D, Hashimoto S, Watanabe T: The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients (Letter). Diabetes Care 24:953-954, 2001